주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
The Liver Meeting 2024
15 Nov - 19 Nov, 2024, United States OLD
Alcoholic drinks up risk of death in young adults with MASLD
2025-01-09
Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.
Beer intake tied to low diet quality
2025-01-09
Among consumers of different types of alcohol, those who consume beer only have the lowest dietary quality compared with those confined to wine or liquor intake or those who consume multiple types of alcohol, according to data presented at TLM 2024.
Elafibranor improves transplant-free survival in patients with PBC
2025-01-09
Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.
Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer
2025-01-09
The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).
Odevixibat shows rapid, sustained benefits in patients with ALGS
2025-01-09
Treatment with odevixibat led to rapid and sustained improvements in pruritus and serum bile acid (sBA) levels among patients with Alagille syndrome (ALGS), according to the ?nal data of the phase III ASSERT-extension (ASSERT-EXT) study presented at The Liver Meeting 2024.
Pooled analysis ASSUREs seladelpar role in PBC
2025-01-09
Results of the phase III ASSURE study support seladelpar ? a novel first-in-class delpar (selective peroxisome proliferator-activated receptor delta agonist) ? for the treatment of primary biliary cholangitis (PBC).
Sex-based gap in liver transplant allocation narrowed with MELD 3.0
2025-01-09
More women are now being included in liver transplant waitlist and undergoing the procedure following the adoption of the updated Model for End-Stage Liver Disease (MELD)?MELD 3.0?with mortality and transplant rates nearly matching those observed in men, according to a retrospective study conducted in the US.
Statins confer protection against portal hypertension, mortality in cirrhosis
2025-01-09
Statins appear to be beneficial to patients with cirrhosis, being associated with reduced risks of portal hypertension and its complications as well as death, according to a study.
Use of antihypertensive drugs tied to HCC risk in MASLD patients with cirrhosis
2025-01-09
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
